Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Alamgir Khan, Komal Zia, Salman Ali Khan, Asaad Khalid, Ashraf N. Abdalla, Marium Bibi & Zaheer Ul-Haq. (2023) Identification of IL-2 inducible tyrosine kinase inhibitors by quantum mechanics and ligand based virtual screening approaches. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-11.
Read now
Read now
Darius Saberi, Anastasia Geladaris, Sarah Dybowski & Martin S. Weber. (2023) Bruton’s tyrosine kinase as a promising therapeutic target for multiple sclerosis. Expert Opinion on Therapeutic Targets 27:4-5, pages 347-359.
Read now
Read now
Anna Wolska-Washer & Tadeusz Robak. (2022) Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 15:3, pages 183-194.
Read now
Read now
Articles from other publishers (30)
Dejan Jakimovski, Stefan Bittner, Robert Zivadinov, Sarah A Morrow, Ralph HB Benedict, Frauke Zipp & Bianca Weinstock-Guttman. (2023) Multiple sclerosis. The Lancet.
Crossref
Crossref
Amanda J. Boyle, Anton Lindberg, Junchao Tong, Dongxu Zhai, Fang Liu & Neil Vasdev. (2023)
Preliminary PET imaging of [
11
C]evobrutinib in mouse models of colorectal cancer, SARS‐CoV‐2, and lung damage: Radiosynthesis via base‐aided palladium‐NiXantphos‐mediated
11
C‐carbonylation
. Journal of Labelled Compounds and Radiopharmaceuticals.
Crossref
Crossref
Julia Krämer, Amit Bar-Or, Timothy J. Turner & Heinz Wiendl. (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology 19:5, pages 289-304.
Crossref
Crossref
Panagiotis Kanatas, Ioannis Stouras, Leonidas Stefanis & Panos Stathopoulos. (2022) B-Cell-Directed Therapies: A New Era in Multiple Sclerosis Treatment. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 50:3, pages 355-364.
Crossref
Crossref
Franz Felix Konen, Nora Möhn, Torsten Witte, Matthias Schefzyk, Miriam Wiestler, Svjetlana Lovric, Karsten Hufendiek, Philipp Schwenkenbecher, Kurt-Wolfram Sühs, Manuel A. Friese, Luisa Klotz, Refik Pul, Marc Pawlitzki, David Hagin, Christoph Kleinschnitz, Sven G. Meuth & Thomas Skripuletz. (2023) Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmunity Reviews 22:5, pages 103312.
Crossref
Crossref
Sarah Dybowski, Sebastian Torke & Martin S. Weber. (2023) Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors. JAMA Neurology 80:4, pages 404.
Crossref
Crossref
A. N. Boyko. (2023) Tyrosine Kinases: Targets for Epigenetic Influences and a New Direction in the Treatment of Multiple Sclerosis. Neuroscience and Behavioral Physiology 53:3, pages 333-336.
Crossref
Crossref
Ganesha Liyanage & Fabienne Brilot. (2022) Targeting B cell dysregulation with emerging therapies in autoimmune demyelinating disorders. Current Opinion in Neurobiology 77, pages 102643.
Crossref
Crossref
Bárbara B. Sousa, Cátia Rebelo de Almeida, Ana F. Barahona, Raquel Lopes, Ana Martins-Logrado, Marco Cavaco, Vera Neves, Luís A. R. CarvalhoCarlos Labão-Almeida, Ana R. Coelho, Marta Leal Bento, Ricardo M. R. M. Lopes, Bruno L. Oliveira, Miguel A. R. B. Castanho, Peter Neumeister, Alexander Deutsch, Gregory I. Vladimer, Nikolaus KrallCristina João, Francisco Corzana, João D. Seixas, Rita Fior & Gonçalo J. L. Bernardes. (2022) Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors. ACS Pharmacology & Translational Science 5:11, pages 1156-1168.
Crossref
Crossref
Tingyu Cao, Zengguang Wang & Xiaodong Zhu. (2022) The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System. Journal of Inflammation Research Volume 15, pages 6427-6438.
Crossref
Crossref
Neeta Garg, Elizabeth Jordan Padron, Kottil W. Rammohan & Courtney Frances Goodman. (2022) Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. Journal of Clinical Medicine 11:20, pages 6139.
Crossref
Crossref
Pablo Villoslada & Sara Llufriu. (2022) Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease. Neurology 99:15, pages 641-642.
Crossref
Crossref
Anastasia Geladaris, Sebastian Torke & Martin S. Weber. (2022) Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?. CNS Drugs 36:10, pages 1019-1030.
Crossref
Crossref
Zeya Yan, Feng Gu, Zilan Wang, Jiahao Meng, Xinyu Tao, Qiling Dai, Wei Wang, Meirong Liu & Zhong Wang. (2022) Safety and efficacy of tyrosine kinase inhibitors for the treatment of multiple sclerosis: A systematic review and meta-analysis from randomized controlled trials. Frontiers in Neurology 13.
Crossref
Crossref
Özgür Yaldizli & Tobias Derfuss. (2022) All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Commentary. Multiple Sclerosis Journal 28:10, pages 1502-1503.
Crossref
Crossref
Fioravante Capone, Angela Albanese, Giorgia Quadri, Vincenzo Di Lazzaro, Emma Falato, Antonio Cortese, Laura De Giglio & Elisabetta Ferraro. (2022) Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review. Frontiers in Neurology 13.
Crossref
Crossref
Jianian Hu, Chongbo Zhao & Jie Lin. (2022) Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity Reviews 21:4, pages 103032.
Crossref
Crossref
Joachim Havla & Reinhard Hohlfeld. (2022) Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair. Neurotherapeutics 19:3, pages 774-784.
Crossref
Crossref
Monica Margoni, Paolo Preziosa, Massimo Filippi & Maria A. Rocca. (2021) Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. Journal of Neurology 269:3, pages 1316-1334.
Crossref
Crossref
Sarah Bailly, Eric Van Den Neste, Thierry Duprez, Marc André & Vincent van Pesch. (2021) Bing–Neel syndrome hidden by multiple sclerosis, a challenging overlay of diseases. Acta Neurologica Belgica 122:1, pages 227-229.
Crossref
Crossref
Brian T. Hopkins, Eris Bame, Bekim Bajrami, Cheryl Black, Tonika Bohnert, Carrie Boiselle, Doug Burdette, Jeremy C. Burns, Luisette Delva, Douglas Donaldson, Richard Grater, Chungang Gu, Marc Hoemberger, Josh Johnson, Sudarshan Kapadnis, Kris King, Mukesh Lulla, Bin Ma, Isaac Marx, Tom Magee, Robert Meissner, Claire M. Metrick, Michael Mingueneau, Paramasivam Murugan, Kevin L. Otipoby, Evelyne Polack, Urjana Poreci, Robin Prince, Allie M. Roach, Chris Rowbottom, Joseph C. Santoro, Patricia Schroeder, Hao Tang, Eric Tien, Fengmei Zhang & Joseph Lyssikatos. (2021) Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. Journal of Medicinal Chemistry 65:2, pages 1206-1224.
Crossref
Crossref
A.N. Boyko. (2022) Tyrosine kinases: a target of epigenetic influences and a new direction in the treatment of multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:7, pages 27.
Crossref
Crossref
Garth E. Ringheim, Matthew Wampole & Kinsi Oberoi. (2021) Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Frontiers in Immunology 12.
Crossref
Crossref
Martin S. WeberJacqueline A. NicholasMichael R. Yeaman. (2021) Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. Neurology Neuroimmunology & Neuroinflammation 8:6.
Crossref
Crossref
Kenji Kufukihara. (2021) Anti‐B cell therapies in multiple sclerosis. Clinical and Experimental Neuroimmunology 12:4, pages 228-237.
Crossref
Crossref
Sining Zhu, Jaeyong Jung, Eton Victor, Johann Arceo, Samantha Gokhale & Ping Xie. (2021) Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies. Frontiers in Oncology 11.
Crossref
Crossref
Chiara Brullo, Carla Villa, Bruno Tasso, Eleonora Russo & Andrea Spallarossa. (2021) Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. International Journal of Molecular Sciences 22:14, pages 7641.
Crossref
Crossref
Finn Sellebjerg & Martin S. Weber. (2021) Targeting B cells in multiple sclerosis. Current Opinion in Neurology 34:3, pages 295-302.
Crossref
Crossref
Jiamin Zheng, Jun Wu, Xiao Ding, Hong C. Shen & Ge Zou. (2021) Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 38, pages 127862.
Crossref
Crossref
Tobias Brummer, Tobias Ruck, Sven G. Meuth, Frauke Zipp & Stefan Bittner. (2021) Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Therapeutic Advances in Neurological Disorders 14, pages 175628642110355.
Crossref
Crossref